§ 764.102 except § 764.102(f), which does not apply to applicants for the CL Program.

(b) The applicant must agree to repay any duplicative financial benefits or assistance to CL.

§ 764.234 Rates and terms.

(a) *Rates.* The interest rate:

(1) Will be the Agency's Direct Farm Ownership rate, available in each Agency office.

(2) Charged will be the lower rate in effect either at the time of loan approval or loan closing.

(b) *Terms.* The following terms apply to CLs:

(1) The Agency schedules repayment of a CL based on the useful life of the security.

(2) The maximum term for loans secured by chattels only will not exceed 7 years from the date of the note.

(3) In no event will the term of the loan exceed 20 years from the date of the note.

§ 764.235 Security requirements.

(a) The loan must be secured:

(1) In accordance with requirements established in §§ 764.103 through 764.106; and

(2) In the order of priority as follows:

(i) By real estate, if available, and then

(ii) By chattels, if determined acceptable by the Agency.

(b) [Reserved]

§§ 764.236–764.250 [Reserved]

PART 765—DIRECT LOAN SERVICING—REGULAR

■ 37. The authority citation for part 765 continues to read as follows:

Authority: 5 U.S.C. 301 and 7 U.S.C. 1989.

■ 38. In § 765.101, add paragraph (g) to read as follows:

§ 765.101 Borrower graduation requirements.

* * * * *

(g) CLs are not subject to graduation requirements under this part.

■ 39. In § 765.152, revise paragraph (b)(6) to read as follows:

§ 765.152 Types of payments.

* * * * *

(b) * * *

(6) Refunds of duplicate program benefits or assistance to be applied on CL or EM loans; or

* * * * *

§§ 765.205–765.207 and 765.253 [Amended]

■ 40. In addition to the amendment set forth above, in 7 CFR part 765, remove the word "graduate" and add, in its place, the words "graduate on any program except for CL" in the following places:

■ a. In § 765.205 paragraph (b)(6),

■ b. In § 765.206 paragraph (b)(5),

■ c. In § 765.207 paragraph (c), and

■ d. In § 765.253 paragraph (b).

§ 765.351 [Amended]

■ 41. Amend § 765.351, paragraph (a)(8), by removing the word "credit" and adding, in its place, the words "credit on any program except for CL".

PART 766—DIRECT LOAN SERVICING—SPECIAL

■ 42. The authority citation for part 766 continues to read as follows:

Authority: 5 U.S.C. 301 and 7 U.S.C. 1981(d) and 1989.

■ 43. Amend § 766.107 as follows:

■ a. In paragraph (b) introductory text, add the acronym and punctuation "CL," immediately after the acronym "OL,"

■ b. Revise paragraph (c)(2) to read as set forth below, and

■ c. Add paragraphs (c)(3) and (c)(4) to read as set forth below.

§ 766.107 Consolidation and rescheduling.

* * * * *

(c) * * *

(2) Except for CL and RL loans, the repayment period cannot exceed 15 years from the date of the consolidation and rescheduling.

(3) The repayment schedule for RL loans may not exceed 7 years from the date of rescheduling.

(4) The repayment schedule for CLs may not exceed 20 years from the date of the original note or assumption agreement.

* * * * *

■ 44. Amend § 766.108 as follows:

■ a. In paragraph (a) introductory text, add the acronym and punctuation "CL," immediately after the acronym "RHF," and

■ b. Add paragraph (b)(2)(v) to read as set forth below.

§ 766.108 Reamortization.

* * * * *

(b) * * *

(2) * * *

(v) CLs may not exceed 20 years from the date of the original note or assumption agreement.

* * * * *

Signed in Washington, DC, August 31, 2010.

Jonathan W. Coppess,

Administrator, Farm Service Agency.

[FR Doc. 2010–22070 Filed 9–2–10; 8:45 am]

BILLING CODE 3410–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510

[Docket No. FDA–2010–N–0002]

New Animal Drugs; Change of Sponsor's Name and Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's name from Alpharma, Inc., to Alpharma LLC. The sponsor's mailing address will also be changed.

DATES: This rule is effective September 3, 2010.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–276–8307, email: *david.newkirk@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: Alpharma, Inc., 440 Rte. 22, Bridgewater, NJ 08807 has informed FDA that it has changed its name and address to Alpharma LLC, 400 Crossing Blvd., Bridgewater, NJ 08807. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c) to reflect this change.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1), revise the entry for "Alpharma Inc."; and in the table in paragraph (c)(2), revise the entry for "046573" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * * * *	
Alpharma LLC, 400 Crossing Blvd., Bridgewater, NJ 08807.	046573
* * * * *	

(2) * * *

Drug labeler code	Firm name and address
* * * * *	
046573	Alpharma LLC, 400 Crossing Blvd., Bridgewater, NJ 08807.
* * * * *	

Dated: August 31, 2010.

Elizabeth Rettie,

Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 2010–22044 Filed 9–2–10; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522

[Docket No. FDA–2010–N–0002]

New Animal Drugs; Change of Sponsor; Penicillin G Benzathine and Penicillin G Procaine Suspension; Penicillin G Procaine Aqueous Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for two new animal drug applications (NADAs) from G. C. Hanford Manufacturing Co. to Norbrook Laboratories, Ltd.

DATES: This rule is effective September 3, 2010.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–276–8307, e-mail: *david.newkirk@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: G. C. Hanford Manufacturing Co., P.O. Box 1017, Syracuse, NY 13201, has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 65–493 for Penicillin G Procaine Aqueous Suspension and NADA 65–500 for Penicillin G Benzathine and Penicillin G Procaine Suspension, to Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland. Accordingly, the agency is amending the regulations in 21 CFR 522.1696a and 522.1696b to reflect the transfer of ownership.

In addition, FDA has noticed that "G. C. Hanford" and "GTC Biotherapeutics, Inc." are not spelled correctly in the listing of sponsors of approved NADAs. At this time, the table in 21 CFR 510.600(c)(1) is amended. This action is being taken to improve the accuracy of the regulations.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 522

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

■ 2. In § 510.600, in the table in paragraph (c)(1), in the entry for "G. C. Biotherapeutics, Inc.", remove "G. C." and in its place add "GTC"; and in the entry for "GTC Hanford Manufacturing Co.", remove "GTC" and in its place add "G. C.".

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 4. In § 522.1696a, revise paragraphs (b)(1), (b)(2), (d)(2)(ii)(A), and (d)(2)(iii) to read as follows:

§ 522.1696a Penicillin G benzathine and penicillin G procaine suspension.

* * * * *

(b) * * *

(1) Nos. 000856, 049185, 055529, and 061623 for use as in paragraph (d)(1) of this section.

(2) Nos. 055529, 059130, and 061623 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(2)(iii) of this section.

* * * * *

(d) * * *

(2) * * *

(ii) * * *

(A) Treatment of bacterial pneumonia (*Streptococcus* spp., *Actinomyces pyogenes*, *Staphylococcus aureus*); upper respiratory infections such as rhinitis or pharyngitis (*A. pyogenes*); blackleg (*Clostridium chauvoei*).

* * * * *

(iii) *Limitations.* Limit treatment to two doses. Not for use within 30 days of slaughter. For Nos. 049185, 055529, 059130, and 061623: A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

■ 5. In § 522.1696b, revise paragraphs (b)(1), (b)(2), (d)(2)(i)(A), and (d)(2)(iii)(B) to read as follows:

§ 522.1696b Penicillin G procaine aqueous suspension.

* * * * *

(b) * * *

(1) Nos. 053501, 055529, and 059130 for use as in paragraph (d) of this section.

(2) No. 061623 for use as in paragraph (d)(2) of this section.

* * * * *

(d) * * *

(2) * * *

(i) * * *

(A) For Nos. 053501, 055529, 059130, and 061623: Continue treatment at least 48 hours after symptoms disappear.

* * * * *

(iii) * * *

(B) For Nos. 055529 and 059130: Continue treatment at least 1 day after symptoms disappear (usually 2 or 3 days).

Dated: August 31, 2010.

Elizabeth Rettie,

Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 2010–22042 Filed 9–2–10; 8:45 am]

BILLING CODE 4160–01–S